Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
Harga saat ini dari BIORQ adalah $0 USD — turun sebesar -90% dalam 24 jam terakhir. Pantau kinerja harga saham Biora Therapeutics lebih dekat di grafik.
Apa simbol saham Biora Therapeutics?▼
Tergantung pada bursa, simbol saham dapat berbeda. Misalnya, di bursa , saham Biora Therapeutics diperdagangkan dengan simbol BIORQ.
Apakah harga saham Biora Therapeutics sedang naik?▼
Saham BIORQ naik +0% dibandingkan minggu sebelumnya, naik +0% selama sebulan terakhir, namun dalam setahun terakhir Biora Therapeutics menunjukkan penurunan sebesar -100%.
Berapa kapitalisasi pasar Biora Therapeutics?▼
Hari ini Biora Therapeutics memiliki kapitalisasi pasar sebesar 4.52
Berapa pendapatan Biora Therapeutics tahun lalu?▼
Pendapatan Biora Therapeutics tahun lalu berjumlah 8,000 USD.
Berapa pendapatan bersih Biora Therapeutics tahun lalu?▼
Pendapatan bersih BIORQ untuk tahun lalu adalah -248.23M USD.
Berapa jumlah karyawan Biora Therapeutics?▼
Per April 03, 2026, perusahaan memiliki 58 karyawan.
Biora Therapeutics berada di sektor apa?▼
Biora Therapeutics beroperasi di sektor Health Care.